Find Novel Immunology Drugs in Clinical Development in UNITED STATES

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: RA Capital Management

Deal Size: $50 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 27, 2020

Details:

The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.

Lead Product(s): T cells therapy

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Vida Ventures

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 13, 2020

Details:

Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease.

Lead Product(s): T cells therapy

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $587.5 million Upfront Cash: $17.5 million

Deal Type: Collaboration January 13, 2020

Details:

Kyverna will be conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option for further development and commercialization of these programs.

Lead Product(s): Antibodies

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Pandion Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: SAB Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 07, 2020

Details:

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.